PMID- 34691250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211026
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 22
IP  - 6
DP  - 2021 Dec
TI  - New prognostic factors and scoring system for patients with acute myeloid 
      leukemia.
PG  - 823
LID - 10.3892/ol.2021.13084 [doi]
LID - 823
AB  - Acute myeloid leukemia (AML) is a malignant disease originating from myeloid 
      hematopoietic stem or progenitor cells. It is important to identify molecules 
      associated with the prognosis of AML and conduct an individual risk assessment 
      for different patients. In the present study, the RNA expression profile of 132 
      patients with AML and 337 healthy individuals were downloaded from the University 
      of California Santa Cruz Xena and the Genotype-Tissue Expression project 
      databases. Differentially expressed mRNA (DEmRNA) transcripts between normal 
      blood and AML blood were identified. Among these, prognosis-associated signature 
      mRNA molecules were screened using univariate Cox and least absolute shrinkage 
      and selection operator regression. A total of four genes, namely, family with 
      sequence similarity 124 member B (FAM124B), 4-hydroxyphenylpyruvate 
      dioxygenase-like protein (HPDL), myeloperoxidase (MPO) and purinergic receptor 
      P2Y1 (P2RY1), were identified using multivariate Cox regression analysis and were 
      used to construct a prognostic scoring system. Moreover, the expression levels of 
      HPDL and MPO were higher in the samples with high immunity scores and estimate 
      scores (sum of stromal score and immune score), compared with those with low 
      scores. Reverse transcription-quantitative PCR and western blot analysis were 
      used to confirm the upregulation of the four candidate genes in AML cell lines as 
      well as in clinical AML samples. In summary, the present study identified a novel 
      mRNA-based prognostic risk scoring system for patients with AML. The four genes 
      used in this scoring system may also play an important role in AML.
CI  - Copyright: (c) Kuang et al.
FAU - Kuang, Ye
AU  - Kuang Y
AD  - Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China.
FAU - Wang, Yang
AU  - Wang Y
AD  - Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China.
FAU - Cao, Xianghong
AU  - Cao X
AD  - Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China.
FAU - Peng, Chuanmei
AU  - Peng C
AD  - Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China.
FAU - Gao, Hui
AU  - Gao H
AD  - Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20211011
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC8527825
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - biomarker
OT  - mRNA
OT  - prognosis
OT  - risk score
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/26 06:00
MHDA- 2021/10/26 06:01
PMCR- 2021/10/11
CRDT- 2021/10/25 06:27
PHST- 2021/06/15 00:00 [received]
PHST- 2021/09/01 00:00 [accepted]
PHST- 2021/10/25 06:27 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2021/10/26 06:01 [medline]
PHST- 2021/10/11 00:00 [pmc-release]
AID - OL-22-06-13084 [pii]
AID - 10.3892/ol.2021.13084 [doi]
PST - ppublish
SO  - Oncol Lett. 2021 Dec;22(6):823. doi: 10.3892/ol.2021.13084. Epub 2021 Oct 11.